我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- Anthem Biosciences, a Contract Research, Development, and Manufacturing Organization (CRDMO), is launching a ₹3,395 crore IPO from July 14-16 with shares priced at ₹540-570 each. - The company reported strong financial performance with revenue growing 30% year-on-year to ₹1,844 crore in FY25 and profit after tax increasing 23% to ₹451 crore. - The IPO is entirely an offer for sale by existing shareholders, meaning no proceeds will go to the company for expansion or operations. - Anthem operates integrated pharmaceutical services from drug discovery to manufacturing, specializing in complex fermentation-based APIs including probiotics, enzymes, and biosimilars.
